Alice Melão,  —

A diet that keeps blood sugar levels in check can help Angelman syndrome patients reduce the number epileptic seizures they have, Massachusetts researchers report. The Massachusetts General Hospital team said the diet, called low glycemic index treatment, or LGIT, also improved patients’ cognition, physical function, and behavior. Their study, published in …

A case of bladder cancer in a young woman with Angelman syndrome suggests a potential association between these two conditions. Reported by East Tennessee State University researchers, the case was described in “Urothelial Carcinoma in a 22-Year-Old Female with Angelman Syndrome,” published in Case Reports in Urology.

More than 90 percent of Angelman syndrome cases are caused by genetic abnormalities affecting the E3 ubiquitin ligase (UBE3A) gene. In the study “A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders,” a team at Georgia State University reviewed what is known about this enzyme…

Boston-based FDNA has launched a new global initiative to promote medical research collaborations and to develop new precision approaches for diagnosing and treating disease, including Angelman syndrome, the company said. The initiative, called Genomics Collaborative, uses computer analysis and artificial intelligence technologies to integrate genetic information with the physical and biological characteristics…

Mutations in the VARS2 gene, which is involved in mitochondrial function, may lead to an Angelman syndrome-like disorder, according to a case report published in the journal Human Genomics. The case was presented by a research team at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia,…

Ovid Therapeutics will present new data from its lead investigational drug, OV101, to treat neurodevelopmental symptoms of diseases like Angelman syndrome and Fragile X syndrome, at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop. The conference begins today in Saint-Alexis-des-Monts, Quebec. On Oct. 15, Dr. Brett Abrahams, Ovid’s director and head…

An analysis of the most common causes of hospitalization among patients with Angelman syndrome reveals that they differ based on age and gender. The study, published in the Journal of Applied Research in Intellectual Disabilities, shows common healthcare needs among sub-groups of Angelman patients, which may help design tailored…

Using a process called imprinting, researchers at Howard Hughes Medical Institute have discovered a new mechanism that cells use to control which genes are turned off during fetal development. The finding adds new knowledge to the underling mechanisms of developmental and neurological disorders, such as Angelman syndrome or Beckwith-Wiedemann…

Ovid Therapeutics is conducting two clinical trials assessing its lead candidate OV101 for the treatment of adolescents and adults with Angelman syndrome. Both trials are currently enrolling participants. “Ovid has a clear strategy and business plan to build a neurology company focused on rare disorders of the brain,” Jeremy…